ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high (MSI‐H) molecular subtype

Anti‐HER2 therapy is indicated for erb‐b2 receptor tyrosine kinase 2 (ERBB2)‐amplified/overexpressing endometrial carcinoma (EC). Mutations constitute another mode of ERBB2 activation, but only rare ERBB2‐mutated ECs have been reported. We sought to characterize the clinicopathologic and genetic fea...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Melica Nourmoussavi Brodeur, Pier Selenica, Weining Ma, Sara Moufarrij, Christian Dagher, Thais Basili, Nadeem R. Abu‐Rustum, Carol Aghajanian, Qin Zhou, Alexia Iasonos, Lora H. Ellenson, Britta Weigelt, M. Herman Chui
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Wiley 2024-10-01
Σειρά:	Molecular Oncology
Θέματα:	endometrial cancer ERBB2 HER2 microsatellite instability mutation
Διαθέσιμο Online:	https://doi.org/10.1002/1878-0261.13698
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!